74 results on '"Guchelaar, Henk Jan"'
Search Results
2. A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients
3. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
4. Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy
5. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
6. A nomogram to predict severe toxicity in DPYD wild‐type patients treated with capecitabine‐based anticancer regimens
7. Reply to: Temporary Like Achilles: pre‐emptive germline pharmacogenetic testing
8. Pharmacogenetics: optimising prescribing in primary care
9. Development and Bioequivalence of 3D ‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine
10. Genome‐wide association study of methotrexate‐induced liver injury in rheumatoid arthritis patients
11. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation
12. Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters”
13. Patient reporting of sexual adverse events on an online platform for medication experiences
14. Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients
15. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
16. Contribution of common and rare genetic variants in CEP72 on vincristine‐induced peripheral neuropathy in brain tumour patients
17. Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics
18. Concomitant use of isavuconazole and CYP3A4/5 inducers : Where pharmacogenetics meets pharmacokinetics
19. Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK
20. Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
21. An Electronic Health Record Text Mining Tool to Collect Real‐World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma
22. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices
23. Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics
24. One non‐believer: Response to “Obviously Nine Believers: Actionable Germline Genetic Variants for Pre‐emptive Pharmacogenetic Testing”
25. StandardizingCYP 2D6Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
26. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
27. Development of the PG x‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing
28. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device
29. Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
30. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
31. Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety
32. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study
33. Exploring genetic and non‐genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients
34. Evaluation of an oral uracil loading test to identify DPD‐deficient patients using a limited sampling strategy
35. Dried blood spot analysis for therapeutic drug monitoring of pazopanib
36. Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer
37. Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry
38. The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists
39. Reply
40. The Oxford Handbook of Clinical Pharmacy
41. Preventing adverse drug events in hospital practice: an overview
42. Reply
43. Reply
44. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent‐onset rheumatoid arthritis
45. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single‐nucleotide polymorphisms in genes coding for folate pathway enzymes
46. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio
47. 5‐fluorocytosine‐related bone‐marrow depression and conversion to fluorouracil: a pilot study
48. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production
49. Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection
50. The antioxidantN-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.